Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Stock-based compensation expense in R&D by Year
Stock-based compensation expense in R&D ($M) ($M)
Moderna Stock-based compensation expense in R&D: $291M in FY2025, up 10.2% from a year earlier. That is the highest of the 8 years on record here.
Latest, FY2025
291
Period ended Dec 31, 2025
Change on a year earlier
+10.2%
264 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Note 14 (Stock-Based Compensation).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Stock-based compensation expense in R&D ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 291 | +10.2% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 264 | +68.2% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 157 | +68.8% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 93 | +36.8% | Form 10-K (filed 2025-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 68 | +21.4% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 56 | +16.7% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 48 | +27.3% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 37.7 | – | Form 10-K (filed 2021-02-26) ↗ |
Cite this data
StockData. (2026). Moderna Stock-based compensation expense in R&D ($M), annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rd-sbc
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.